The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Look at the companies listed having eccleston place as a registered address then accounting firm used then how any firm helped to trade on the market has performed you’ll see a pattern if you can’t then the problem is you not accepting the facts
Is this now the new low, i duno, i lost count
The MGC ZAM App is a huge opportunity for MGC's epilepsy treatment, CannEpil, It's estimated that about 1.2 percent of U.S. people have active epilepsy ( 3.4 million people) and more than 65 million people globally. Plus about 1 in 26 people will develop epilepsy at some point during their lifetime. In the UK it's estimated 633,000 people are living with epilepsy. The global antiepileptic drugs (AED) market size is projected to reach USD 20.33 billion by 2026. CannEpil could on this basis be worth a fortune to MGC investors and could prove to be invaluable for those with epilepsy. Big pharma will be watching this, make no mistake with a view to licence CannEpil or takeover MGC at some stage.
Good luck, Brighty
Let's hope the trial will bring good news for both shareholders and epilepsy sufferers (see intial post)
More than you can imagine
I see we have a new poster posting rubbish stright off wander how many shares he owns.???
Anyone still invested in mgc needs to face the reality that this will never come to any big pay day for investors.
Today’s announcement more proof of how it’s run.
Sucking money with no delivery on any promises.
All gone quiet on the socials new website designed by a child or on a free app.
But we can say it’s along term hold instead of facing reality it’s a rotten egg.
Lucksin, depend when you picked up a bag or too to rate if it is a write off for a quick trade. That boat sailed after their oh so boastful enterance into the market..... only for it to sell us dummys and not deliver achievements, look back at the keen words of 180 india trial for their 'covid' treatment.... 370 days or summink that is now. So yeah sadly some bagging needs to be done just to break even, so for me a bottom.draw write off.
Where do you propose MGC get the money to fund their business, staff need paying, without staff no trials, trials need funding. No guarantees this will become fruitful but the chances are greater than lesser in my opinion. I'm afraid this is a long term hold.
All the signs are there nothing will be delivered for shareholders left holding the poo stick whilst Roby and co disappear into the sunset
.... Can only be seen as a "write off" if you are looking for a quick trade!
It's also worth noting in addition to today's very positive RNS about CimetrA that MGC has announced two excellent clinical results demonstrating full safety and preliminary efficacy profiles in Dementia treatment with CogniCann® and Glioblastoma for tumours. The recent data readouts from MGC will certainly be interesting to global pharmas moving forward for licencing or M&A activity. Hopefully 2023 will be the year when the wider market cottons on to what's unfolding here. Good luck, Brighty
Hope you are right brighty as this has become a write-off.
Agreed it sounds very promising. Ive got big numbers invested here and have been for 2 years I am currently underwater but I am of the same view patience will reward me greatly. MXC are keeping the markets updated on a regular basis and do seem keen to keep us all informed they also have a very positive outlook on their products and from an investment point of view I am happy. would be nice to no the time frames of trail and when the drug could go to market
R & D departments and M&A specialists at big pharma are going to be all over this research. All the signs are clearly pointing to a big new revenue stream opening up in the pharma sector and MGC is leading the way. At some stage a major pharma is going to either licence CimetrA or buy out MGC. It's a waiting game but with every positive RNS highlighting its potency in the treatment of inflammatory diseases MGC is becoming more and more interesting from an investment perspective.
Highlights from the RNS today:
· MGC Pharma has completed an in-vitro pre-clinical study on CimetrA™'s mechanism of action (MoA)
· The study, which was carried out at the GLP-Certified Science in Action Lab, in Ness Ziona, Israel, examined the mechanism underlying the CimetrA™-mediated anti-inflammatory effect on human Peripheral Blood Mononuclear Cells (PBMC)
· The study demonstrated the inhibitory effect of CimetrA™ on the mRNA expression and, as a result, on the secretion of IL-32 proteins and the subsequent suppression of inflammation and inflammatory cytokines
· Additional findings show that CimetrA™ increases intracellular HO-1 the antioxidant activity in cells, protecting against oxidative stress that causes the inflammation
· Further demonstrates CimetrA™'s ability to be extended into the anti-inflammatory market.
* The study showed an increase in intracellular Heme-Oxygenase-1 (HO-1) levels (Figure 3). HO-1 is an enzyme which facilitates the breakdown of metabolites in the cell, enhancing the antioxidant activity and providing protection against oxidative stress, which can cause inflammation. This is a further indication as to the CimetrA™ MoA and its treatment of inflammatory disease including COVID-19, seasonal cold and flu, among others.
In summary, "We conclude that the presence of the IL-32 mRNA protein plays a critical role in the secretion of the cytokines (Figure 1), such as tumour necrosis factor-alpha (TNF-a) and IL-6 (Figure 2), that cause inflammation. Control of this protein is then the fundamental pathway to manage and reduce inflammation".
It's also worth noting that this very encouraging data announced today is to be presented to the US Food and Drug Administration (FDA) as part of the application to register CimetrA.
It won't be long before big pharma really starts to take a commercial interest in MGC. Watch this space....
Good luck, Brighty
I hope so too, but their cash situation is a problem. From reading the latest bulletin it looks like we are in for further dilution of up to 20% as the terms of the Mercer CLN deal are changing. CLNs arent great as it is as the market is continuously flooded with more shares and Mercer will control the price, perhaps selling on any spike. This, other than the lack of revenue is the 2nd problem. Perhaps someone with a better knowledge of CLNs who has read the recent report could share their view. We need some serious revenue, and soon, but with all pharma its high risk, high returns if MGC can capitalise on something. Breakthrough epilepsy treatment would be a wonderful thing for sufferers.
Train smash, train smash, high voltage!
I invested in MGC after a friend's daughter died of incurable epilepsy at the age of 23. I hope for other like her MGC is a resounding sucess
We should be hearing encouraging news shortly on MGC distributing the first CannEpil units to EU territories and the UK during Q1 2023. See full details at:
https://www.asx.com.au/asxpdf/20230228/pdf/45m5r4hpgs6nb8.pdf
Good luck, Brighty
@ mannnan..........you really bring so much value to this forum with your varied and informative posts, not !
Lol just popped on to see if anyone noticed... boom! Lol
Here you go another new low again
Going to zero... flatline. :(
Not the last.....